Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Gardasil Sales Climb In Third Quarter; HPV Vaccine Generates $70 Mil.

Executive Summary

Merck's human papilloma virus vaccine Gardasil generated $70 mil. in sales during its first full quarter on the market, the company reported

You may also be interested in...



Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady

Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics

Therapeutic Biologics Approvals Up In 2006, Overall BLA Approvals Steady

Overall 2006 biological license application approvals held steady from 2005 at 10 approvals, but the year saw a significant increase in approvals of therapeutic biologics

Gardasil Reimbursement Issues To Be Resolved In Early 2007, Merck Says

Merck expects reimbursement issues for its human papillomavirus vaccine Gardasil to be resolved by early 2007, Merck Vaccines President Margaret McGlynn said Dec. 12

Related Content

UsernamePublicRestriction

Register

PS047708

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel